Stock Rich List
#163 on the corporate holders of 809 holders

Artal International Management S.A.

10% owner at Scholar Rock Holding; Director at CAVA Group; Director at Lexicon Pharmaceuticals.

$1.08B
in disclosed stock, +$2.9M (+0.27%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
163rd of 809
Companies held
4
Largest holding
SRRK, 42.1% of total
Latest SEC filing
Jun 15, 2026
Listed but not counted
$24.0M

What the $1.08B is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Scholar Rock Holding SRRK
Common Stock
Directly9,059,507$50.37$456M42.1%Form 4, Apr 28, 2023
CAVA Group CAVA
Common Stock
Directly6,507,990$51.23$333M30.8%Form 4, Jun 15, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Indirectly (see filing footnote)175,156,062$1.67$293M27.0%Form 4, Apr 30, 2026
Crescent Biopharma CBIO
Common Stock
Directly85,891
split-adjusted
$12.91$1.1M0.1%Form 4, Feb 24, 2023

Share counts are the amounts Artal International Management S.A. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Artal International Management S.A.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Lexicon Pharmaceuticals LXRX
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
7,362,368$1.67$12.3M—Form 4, Feb 2, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Through Invus US Partners LLC
Held by a company or fund the insider manages
5,451,204$1.67$9.1M—Form 4, Feb 2, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Through Avicenna Life Sci Master Fund LP
Held by a company or fund the insider manages
1,538,462$1.67$2.6M—Form 4, Feb 2, 2026

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Jun 15, 2026SoldCAVA3,000,000$90.30$271MView
Feb 2, 2026BoughtLXRX1,538,462$1.30$2.0MView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
160Glencore International AG
10% owner, Bunge Global SA
$1.10B−$47.2M (−4.13%)
161MP 13 Ventures, LLC
10% owner, ImmunityBio
$1.09B−$21.7M (−1.94%)
162IDG-Accel China Capital GP II Associates Ltd.
10% owner, Circle Internet
$1.09B−$30.0M (−2.68%)
163Artal International Management S.A.
10% owner, Scholar Rock Holding
$1.08B+$2.9M (+0.27%)
164GEI Capital VII, LLC
10% owner, WESCO International
$1.07B−$22.1M (−2.03%)
165BX Vine Intermediate Holdco L.P.
10% owner, Expand Energy
$1.06B−$26.0M (−2.40%)
166T11 Hhc, LLC
10% owner, Hyatt Hotels
$1.06B−$41.3M (−3.76%)

Other Scholar Rock Holding insiders

All SRRK insiders

Questions

How much stock does Artal International Management S.A. own?

Artal International Management S.A. holds $1,083,351,167 in listed stock based on SEC filings and current prices, mostly Scholar Rock Holding (SRRK). That ranks 163rd on the Stock Rich List.

Is this Artal International Management S.A.'s net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Artal International Management S.A. last buy or sell stock?

The most recent open-market trade on file is a sale of 3,000,000 CAVA shares on Jun 15, 2026 at $90.30.

Files jointly with Raymond Debbane, SEC filer 1053905, SEC filer 1460840, SEC filer 1841311.